# Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

> **NCT03634332** · PHASE2 · UNKNOWN · sponsor: **Pancreatic Cancer Research Team** · enrollment: 35 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
- Pancreatic Neoplasms

## Interventions

- **DRUG:** PEGPH20
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03634332
- **Lead sponsor:** Pancreatic Cancer Research Team
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2020-10
- **Final completion:** 2021-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2019-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634332, "Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03634332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*